1
|
Andries J, Viranaicken W, Cordonin C, Herrscher C, Planesse C, Roquebert B, Lagrange-Xelot M, El-Kalamouni C, Meilhac O, Mavingui P, Couret D, Gadea G, Despres P. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech). Sci Rep 2022; 12:5999. [PMID: 35397679 PMCID: PMC8994064 DOI: 10.1038/s41598-022-10057-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 03/16/2022] [Indexed: 01/07/2023] Open
Abstract
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine comirnaty is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in comirnaty-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from comirnaty vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine comirnaty.
Collapse
Affiliation(s)
- Jessica Andries
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Wildriss Viranaicken
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Colette Cordonin
- Plate-Forme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Charline Herrscher
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Cynthia Planesse
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Bénédicte Roquebert
- Laboratoire CERBA, Parc d'activités « Les Béthunes », 95310, Saint-Ouen-l'Aumône, France
| | - Marie Lagrange-Xelot
- Centre Hospitalier Felix Guyon, Centre Hospitalier Universitaire-La Réunion, 97000, Saint-Denis, La Réunion, France
| | - Chaker El-Kalamouni
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Olivier Meilhac
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Patrick Mavingui
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - David Couret
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,Groupe Hospitalier Sud Réunion, Centre Hospitalier Universitaire-La Réunion, 97410, Saint-Pierre, La Réunion, France
| | - Gilles Gadea
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,IRCM, U1194, MetaSarc Team, 34298, Montpellier, France
| | - Philippe Despres
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
| |
Collapse
|